Obesity and outcomes in patients hospitalized with pneumonia  by Kahlon, S. et al.
Obesity and outcomes in patients hospitalized with pneumonia
S. Kahlon1, D. T. Eurich2, R. S. Padwal1, A. Malhotra3, J. K. Minhas-Sandhu2, T. J. Marrie4 and S. R. Majumdar1,2,5
1) Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, 2) Department of Public Health Sciences, School of Public Health,
University of Alberta, Edmonton, AB, Canada, 3) Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA,
4) Department of Medicine, Faculty of Medicine, Dalhousie University, Halifax, NS and 5) Faculty of Pharmacy and Pharmaceutical Sciences, University of
Alberta, Edmonton, AB, Canada
Abstract
Studies suggest obesity is paradoxically associated with better outcomes for patients with pneumonia. Therefore, we examined the
impact of obesity on short-term mortality in patients hospitalized with pneumonia. For 2 years clinical and radiographic data were pro-
spectively collected on all consecutive adults admitted with pneumonia to six hospitals in Edmonton, Alberta, Canada. We identified
907 patients who also had body mass index (BMI, kg/m2) collected and categorized them as underweight (BMI < 18.5), normal (18.5 to
<25), overweight (25 to <30) and obese (>30). Overall, 65% were >65 years, 52% were female, and 15% reported recent weight loss.
Eighty-four (9%) were underweight, 358 (39%) normal, 228 (25%) overweight, and 237 (26%) obese. Two-thirds had severe pneumonia
(63% PSI Class IV/V) and 79 (9%) patients died. In-hospital mortality was greatest among those that were underweight (12 [14%]) com-
pared with normal (36 [10%]), overweight (21 [9%]) or obese (10 [4%], p <0.001 for trend). Compared with those of normal weight,
obese patients had significantly lower rates of in-hospital mortality in multivariable logistic regression analyses: adjusted odds ratio
(OR), 0.46; 95% CI, 0.22–0.97; p 0.04. However, compared with patients with normal weight, neither underweight (adjusted OR, 1.13;
95% CI, 0.54–2.4; p 0.7) nor overweight (adjusted OR, 0.94; 95% CI, 0.52–1.69; p 0.8) were associated with in-hospital mortality. In
conclusion, in patients hospitalized with pneumonia, obesity was independently associated with lower short-term mortality, while
neither being underweight nor overweight were. This suggests a protective influence of BMIs > 30 kg/m2 that requires better mechanis-
tic understanding.
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Introduction
Obesity is associated with increased co-morbidity (e.g. diabe-
tes, hypertension, sleep apnoea) and higher mortality directly
proportional to increases in body mass index (BMI) [1–3].
Obesity is also independently associated with an increased
risk of acquiring infections such as community-acquired pneu-
monia (CAP) [4,5]. Furthermore, obesity could lead to
worse outcomes in those who develop infections, perhaps as
a result of dysregulation of the inflammatory cascade involv-
ing increased levels of cytokines, adiponectin and leptin and
exaggerated macrovascular and microvascular responses
[4,6]. Obesity also leads to impairments in lung function that
include adverse changes in mechanics and airway resistance
and impaired gas exchange [7,8]. Last, the accumulation of
obesity-related co-morbidities might lead to increased pneu-
monia-related mortality [8].
Conversely, low weight, especially if associated with malnu-
trition, may also be a risk factor for acquiring infections such
as pneumonia and having poorer infection-related outcomes
[8–13]. Unlike the case for obesity, the underlying aetiology
of the weight loss (e.g. malignancy, substance use, cardiopul-
monary cachexia) is often thought to be the mechanism
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underlying increased mortality and poorer pneumonia-related
outcomes [1,8].
Given that obesity is associated with both an increased
risk of developing pneumonia and an increased risk of total
mortality, it could be assumed that obese individuals would
have worse pneumonia-related outcomes. However, a few
studies indicate that obesity may have a protective effect
against pneumonia-related mortality [12,14,15]. This so-called
‘obesity paradox’ is poorly understood for acute infections,
and therefore we examined the relationship between
increased BMI and pneumonia-related mortality. We hypoth-
esized that compared with normal weight, obesity would be
associated with decreased in-hospital mortality.
Methods
Setting and Subjects
From 2000–2002, data were collected on a prospective
cohort of 3415 people (>17 years) with community-acquired
pneumonia who were admitted to six hospitals in Edmonton
(population  1 million), Alberta, Canada, and managed
according to a clinical pathway. Detailed descriptions of the
cohort and data collection methods have been previously
published [16,17]. To enter the cohort, subjects had to have
signs and symptoms of pneumonia (defined as ‡2 of the fol-
lowing: cough, pleurisy, shortness of breath, temperature
>38C, crackles, or bronchial breathing on auscultation) and
a chest radiograph interpreted by the treating physicians as
consistent with pneumonia. All patients were cared for
according to a validated clinical pathway that had triage and
site-of-care suggestions based on the Pneumonia Severity
Index (PSI) and recommendations for investigations and anti-
biotic treatments. Patients with tuberculosis, cystic fibrosis,
immuno-compromised status (e.g. chronic prednisone or
other immunosuppressing agents) or frank aspiration, those
who were pregnant or breast-feeding and those who
required a direct admission to intensive care unit (ICU) were
excluded. The study was exempted from the informed con-
sent requirement and approved by the Health Research Eth-
ics Board at the University of Alberta (Edmonton, Alberta,
Canada).
Measurements
Data collected included patient sociodemographics (age,
sex, residence), clinical characteristics (vital signs, co-mor-
bidities, laboratory values), functional status, prescription
drug use, vaccination history, and the official chest radio-
graph report as interpreted by a board-certified radiologist
(vs. the interpretation of pneumonia made by the treating
physicians). We categorized patients according to Systemic
Inflammatory Response Syndrome (SIRS) criteria [18] and
stress hyperglycaemia at admission (plasma glucose
>6.1 mM (>110 mg/dL)) [19]. Functional status in the
2 weeks before admission was determined by patient or
proxy interview and classified as completely independent
ambulation or impaired. The Pneumonia Severity Index
(PSI), a validated tool for predicting short-term mortality in
patients with pneumonia, was used to assess disease sever-
ity [16,20].
Independent variable of interest
The study cohort included all individuals with pneumonia
who had a BMI measured at the time of admission to hospi-
tal. Unlike the data prospectively collected for the study
described earlier (e.g. the PSI, chest radiographs), height and
weight were not mandated items. Thus, BMI was only cap-
tured if available in the patients’ medical chart as part of rou-
tine hospital care and was recorded in about one-third of
cases (see Results and Appendices 1–3). Patients were cate-
gorized according to the conventional World Health Organi-
zation (WHO) and National Institutes of Health (NIH) BMI
classification: <18.5 kg/m2 (underweight), 18.5 to <25 kg/m2
(normal), 25 to 30 kg/m2 (overweight), >30 kg/m2 (obese)
[21]. Related to BMI, we also collected information with
respect to weight loss, defined as a self- or proxy-reported
loss of weight of ‡ 5% over the preceding 1 year.
Outcomes
The primary outcome was all-cause in-hospital mortality.
Secondary endpoints included the need for transfer to the
ICU and 30-day all-cause readmission to hospital. For end-
points that took place after hospital discharge, we linked our
cohort to routinely updated and previously validated adminis-
trative healthcare databases using unique but anonymized
identifiers [16].
Analysis
We first plotted BMI against mortality using lowess plots.
Using multivariable logistical regression, we evaluated the
independent association between admission BMI and in-hos-
pital mortality. Individuals with a normal BMI of 18.5–25 kg/
m2 served as the reference group. We did not attempt to
impute missing values for BMI [22]. Unadjusted and adjusted
odds ratios (aORs) and 95% confidence intervals (95% CIs)
were calculated. We only forced pneumonia severity accord-
ing to PSI class and BMI as an ordinal variable into each
model. We then considered variables for inclusion in models
if univariate associations with in-hospital mortality were
p <0.1 or if the variable was maldistributed across BMI
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categories or the variable confounded (>10% change in beta
coefficient) the association between BMI and mortality. The
final multivariable model included age, functional status, prior
pneumococcal vaccination, chest radiograph confirmation,
PSI and BMI. Hereafter, we refer to this as our fully adjusted
model. We used the c-statistic (area under the curve) and
the Hosmer-Lemeshow goodness of fit test to evaluate our
final models.
We then replicated the analysis for in-hospital mortality
after excluding those patients with clinically diagnosed pneu-
monia who eventually had an admission chest radiograph
reported as normal. Although chest radiograph abnormalities
are conventionally used to confirm the diagnosis of pneumo-
nia, patients presenting with serious lower respiratory tract
symptoms and signs are often ‘clinically’ diagnosed with
pneumonia, admitted, and treated as such [23].
Finally, we carried out several sensitivity analyses. First,
we examined the impact of self-reported weight loss on the
outcome of in-hospital mortality. Second, we redid the analy-
ses of in-hospital mortality after excluding patients from
nursing homes, as the current definition of ‘community-
acquired’ does not include nursing home-acquired pneumonia.
Last, we repeated our analytical approach for two non-fatal
endpoints: transfer to intensive care unit (ICU) and 30-day
hospital readmission rates among those discharged home. All
analyses were carried out using SAS version 9.2 (SAS Insti-
tute Inc., Cary, NC, USA).
Results
General characteristics
Of 3415 patients admitted to hospital with pneumonia, 907
(27%) had a BMI measured at admission. There were few
clinically important or statistically significant differences
between those who had BMI measured and those where it
was missing (Appendix 1). The mean age was 68 years
(SD = 17), 48% were female and 17% were from nursing
homes. Nearly two-thirds of patients (63%) presented with
severe pneumonia (Pneumonia Severity Index class IVor V);
79% had two or more SIRS criteria and 64% had stress
hyperglycaemia at admission.
BMI and weight
The mean weight for the entire cohort was 73 kg (SD = 23)
and the mean BMI was 27 (SD = 8). There were 84 (9%),
358 (39%), 228 (25%) and 237 (26%) individuals in the under-
weight, normal weight, overweight and obese categories,
respectively. (As an aside, in the Edmonton health region, it
has been estimated that 34% of adults are overweight and
18% obese [24].) Of note, fully 15% of patients reported
recent weight loss. Characteristics of patients stratified by
BMI category are presented in Table 1. Compared with nor-
mal weight patients (reference group), the underweight
patients were more likely to be older, female and nursing
home residents, more likely to report recent weight loss,
and had more severe pneumonia. Conversely, when com-
pared with normal weight patients, the obese patients were
more likely to have diabetes and more likely to present with
shortness of breath and tachycardia, but otherwise they had
less severe pneumonia (Table 1).
In-hospital mortality in the overall cohort
Overall, 79 (9%) patients died in hospital. A curvilinear trend
with higher rates of unadjusted mortality in the underweight
group and much lower unadjusted mortality rates in the
obese group was observed (Fig. 1). Specifically, there were
12 (14%) deaths in the underweight, 36 (10%) in the normal
weight, 21 (9%) in the overweight and 10 (4%) in the obese
category. Table 2 displays those variables significantly associ-
ated with in-hospital mortality in univariable analyses. In
unadjusted analysis, obesity was associated with a significantly
lower risk of mortality compared with the normal weight
category (4% vs. 10% mortality for normal weight; unad-
justed OR, 0.39; 95% CI, 0.19–0.81; p 0.01; Table 3). In fully
adjusted models, obesity was still independently associated
with a significantly lower rate of in-hospital mortality com-
pared with normal weight (adjusted OR, 0.46; 95% CI, 0.22–
0.97; p 0.04). However, mortality rates in the underweight
(adjusted OR, 1.13; 95% CI, 0.54–2.4; p 0.7) and overweight
groups (adjusted OR, 0.94; 95% CI, 0.52–1.69; p 0.8) were
not significantly different compared with normal BMI
(Table 3). The adjusted model for in-hospital mortality per-
formed well according to the c-statistic (0.78, p <0.001) and
goodness-of-fit tests (p 0.92).
In-hospital mortality in those with abnormal chest radio-
graphs
When analyses were restricted to the 680 patients with
chest-radiograph confirmed pneumonia, the findings were
even more striking: there were 12 (17%) in-hospital deaths
in the underweight, 30 (11%) in the normal weight, 19 (11%)
in the overweight and 6 (4%) in the obese category. Even
though the sample size was reduced by 227 patients, the
independent association between obesity and in-hospital
mortality became larger and more significant: adjusted OR,
0.31; 95% CI, 0.12–0.78; p 0.01 ( Table 4). The adjusted
model for in-hospital mortality in this subgroup analysis per-
formed well according to the c-statistic (0.79, p <0.001) and
goodness-of-fit tests (p 0.87).
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Sensitivity analyses
First, inclusion of self-reported weight loss into the multivari-
able models did not alter the relationship observed between
obesity and in-hospital mortality (adjusted OR, 0.47; 95% CI,
0.22–0.99; p 0.05); in addition, the interaction term between
weight loss and BMI was not significant (p 0.17).
Second, after excluding 150 nursing home patients from
analyses, the association between obesity and in-hospital
mortality became even stronger and remained statistically
significant (adjusted OR, 0.25; 95% CI, 0.10–0.63; p 0.004).
Third, there were 179 (20%) ICU transfers and 65 (7%) re-
hospitalizations within 30 days. Compared with normal weight,
there was no independent association between obesity and
ICU transfer (adjusted OR, 0.78; 95% CI, 0.50–1.21; p 0.3) or
30-day readmission rates (adjusted OR, 0.81; 95% CI, 0.41–
1.61; p 0.6 and Table 4). The same pattern held true when
non-fatal endpoints were examined in analyses restricted to
patients with abnormal chest radiographs (Table 5).
Discussion
In a cohort of almost 1000 patients hospitalized for commu-
nity-acquired pneumonia, obese individuals had a significantly
TABLE 1. Characteristics of 907 patients admitted to hospital with pneumonia
Characteristics
BMI categories
p-value<18.5 18.5–25 25–30 >30
N (%) 84 (9) 358 (39) 228 (25) 237 (26)
Weight, kg ± SD 43 ± 7 61 ± 10 76 ± 9 99 ± 24 <0.001
Age, mean ± SD, years 73 ± 16 69 ± 19 69 ± 16 65 ± 16 0.007
Female sex, n (%) 58 (69) 161 (45) 91 (40) 121 (51) <0.001
Non-smoker, n (%) 56 (67) 261 (73) 168 (74) 167 (70) 0.6
Impaired function, n (%) 19 (23) 41 (11) 23 (10) 18 (8) 0.002
Advanced directive, n (%) 17 (20) 45 (13) 14 (6) 13 (6) <0.001
Nursing home, n (%) 23 (27) 64 (18) 35 (15) 28 (12) 0.009
>5% weight loss, n (%) 41 (49) 62 (17) 16 (7) 17 (7) <0.001
Co-morbidities, n (%)
Cardiovascular 41 (49) 171 (48) 119 (52) 125(53) 0.6
COPD 37 (44) 117 (33) 66 (29) 79 (33) 0.1
Diabetes mellitus 2 (2) 13 (4) 12 (5) 24 (10) 0.004
Known cancer 14 (17) 50 (14) 32 (14) 21 (9) 0.2
Chronic kidney disease 9 (11) 55 (15) 40 (18) 30 (13) 0.3
>5 medications, n (%) 9 (11) 49 (14) 44 (19) 53 (22) 0.01
Statins, n (%) 1 (1) 30 (8) 29 (13) 31 (13) 0.006
Pneumovax, n (%) 24 (29) 124 (35) 69 (30) 70 (30) 0.5
Flu vaccine, n (%) 19 (23) 109 (30) 61 (27) 53 (22) 0.1
Pneumonia symptoms, n (%)
Fever 30 (36) 144 (40) 95 (42) 95 (40) 0.8
Cough 60 (71) 235 (66) 160 (70) 169 (71) 0.4
Sputum production 35 (42) 153 (43) 116 (51) 115 (49) 0.2
Shortness of breath 57 (68) 230 (64) 159 (70) 180 (76) 0.03
Pleuritic chest pain 5 (6) 34 (10) 38 (12) 26 (11) 0.4
Altered mental status 20 (24) 61 (17) 30 (13) 26 (11) 0.02
Pneumonia signs, n (%)
Respirations >30 bpm 23 (28) 75 (22) 48 (22) 60 (27) 0.4
Heart rate >100 bpm 43 (51) 166 (46) 91 (40) 124 (52) 0.05
Systolic pressure <90 mmHg 4 (5) 14 (4) 6 (3) 6 (3) 0.6
Crackles on auscultation 30 (36) 137 (38) 90 (39) 88 (37) 0.9
SIRS ‡2 criteria 70 (83) 271 (76) 176 (77) 199 (84) 0.06
Hyperglycaemia >6.1 mM 51 (61) 199 (56) 162 (71) 168 (71) <0.001
Abnormal chest radiograph 70 (83) 280 (78) 169 (74) 161 (68) 0.009
Pneumonia severity index, n (%)
Class I 2 (2) 5 (1) 2 (1) 7 (3) 0.004
Class II 5 (6) 49 (14) 36 (16) 57 (24)
Class III 16 (19) 64 (18) 47 (21) 42 (18)
Class IV 32 (38) 158 (44) 92 (40) 88 (37)
Class V 29 (35) 82 (23) 51 (22) 43 (18)
PSI score, mean ± SD 112 ± 34 106 ± 35 104 ± 34 97 ± 35 <0.001
FIG. 1. Rates of in-hospital pneumonia-related mortality according
to body mass index.
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lower adjusted mortality rate compared with normal weight
patients. This association was relatively strong (56% relative
reduction in mortality) and robust in sensitivity analyses.
Conversely, although underweight patients had the highest
unadjusted mortality, after accounting for recent weight loss
and severity of disease, this was not statistically significant.
Our results are broadly consistent with other research. In
studies of chronic diseases such as coronary artery disease,
heart failure and end-stage renal disease, several studies have
demonstrated the obesity paradox [25–28]. The data for
acute infections such as pneumonia are sparse and less con-
sistent. In a study of 317 patients Corrales Medina et al. [15]
reported a 12% relative reduction (adjusted OR, 0.88; 95%
CI, 0.81–0.96; p <0.01) in pneumonia-related mortality per
unit of BMI although they did not present data according to
BMI category. Inoue et al. [14] found BMI >25 kg/m2 to be
associated with reduced mortality from pneumonia (HR,
0.70; 95% CI, 0.50–0.80; p <0.001) in a cohort of over
100 000 Japanese residents. In a study of 2600 men Lacroix
et al. [12] demonstrated an inverse relationship between BMI
quartiles and pneumonia-related mortality similar to what we
observed. The few studies that have examined pneumonia
have been limited by their lack of clinical data or their lack of
information with respect to recent weight loss or the fact that
their data were drawn from atypical populations [12–15].
If our findings are not the result of chance, what might
explain our results? Obese individuals may have less physiologi-
cal reserve [6] and present to hospital with less severe pneumo-
nia. Our data show lower PSI scores and fewer radiographically
confirmed pneumonias in obese individuals, although all of our
analyses were adjusted for these variables. Alternately (or addi-
tionally), the threshold for admitting an obese patient may be
TABLE 2. Characteristics of patients with pneumonia signif-
icantly associated with in-hospital mortality (univariable
analysis)
Characteristics Alive In-hospital death p-value
N (%) 828 (91) 79 (9)
Body mass index categories, n (%)
<18.5 72 (9) 12 (15) 0.02
18.5–25 322 (39) 36 (46)
25–30 207 (25) 21 (27)
> = 30 227 (27) 10 (13)
Weight, kg ± SD 74 ± 23 68 ± 23 0.02
Age, mean ± SD, years 67 ± 17 77 ± 14 <0.001
Non-smoker, n (%) 585 (71) 67 (85) 0.008
Impaired function, n (%) 80 (10) 21 (27) <0.001
Advanced directive, n (%) 753 (91) 65 (82) 0.01
Nursing home, n (%) 131 (16) 19 (24) 0.06
>5% weight loss, n (%) 117 (14) 19 (24) 0.02
Co-morbidities n (%)
Cardiovascular 401 (48) 55 (70) <0.001
Known cancer 101 (12) 16 (20) 0.04
Chronic kidney disease 117 (14) 17 (22) 0.08
Pneumovax, n (%) 270 (33) 17 (22) 0.04
Pneumonia symptoms, n (%)
Fever 344 (42) 20 (25) 0.005
Cough 577 (70) 47 (59) 0.06
Sputum production 394 (48) 25 (32) 0.007
Pneumonia signs, n (%)
Respirations >30 bpm 180 (23) 26 (35) 0.02
Systolic pressure <90 mmHg 24 (3) 6 (8) 0.03
Abnormal chest radiograph 613 (74) 67 (85) 0.03
Pneumonia severity index, n (%)
Class I 16 (2) 0 (0) <0.001
Class II 146 (18) 1 (1)
Class III 165 (20) 4 (5)
Class IV 336 (41) 34 (43)
Class V 165 (20) 40 (51)
PSI score, mean ±SD 101 ± 34 131 ± 30 <0.001
TABLE 3. Univariable and multi-
variable analysis for in-hospital
mortality of 907 patients with
pneumonia
Unadjusted odds ratios p-value Adjusted* odds ratios p-value
Body mass index categories
<18.5 1.49 (0.74–3.00) 0.3 1.13 (0.54–2.39) 0.7
18.5–25 (reference) 1.00 – 1.00 –
25–30 0.91 (0.52–1.60) 0.7 0.94 (0.52–1.69) 0.8
> = 30 0.39 (0.19–0.81) 0.01 0.46 (0.22–0.97) 0.04
Age > 65 years 3.27 (1.74–6.14) <0.001 2.33 (1.18–4.60) 0.02
Impaired function 3.39 (1.95–5.87) <0.001 2.95 (1.64–5.30) <0.001
Pneumovax 0.57 (0.33–0.99) 0.05 0.39 (0.22–0.70) 0.002
Abnormal chest radiograph 1.96 (1.04–3.69) 0.04 1.84 (0.95–3.55) 0.07
Pneumonia Severity Index Class IV/V 9.66 (3.86–24.2) <0.001 7.11 (2.75–18.38) <0.001
*c-statistic for model = 0.78, p <0.001; Hosmer-Lemeshow goodness-of-fit test, p 0.92.
TABLE 4. Fatal and non-fatal endpoints in 907 patients hospitalized with pneumonia, according to categories of body mass
index
BMI
categories
(kg/m2)
Death,
n (%)
Adjusted *
OR
(95% CI) p-value
Transfer to
ICU, n (%)
Adjusteda
OR (95% CI) p-value
30-day
readmission, n (%)
Adjusteda OR
(95% CI) p-value
<18.5 12 (14) 1.13 (0.54–2.39) 0.7 13 (15) 0.55 (0.28–1.09) 0.1 9 (11) 1.48 (0.66–3.33) 0.3
18.5–25 36 (10) 1.00 REF 79 (22) 1.00 REF 26 (7) 1.00 REF
25.1–30 21 (9) 0.94 (0.52–1.69) 0.8 45 (20) 0.88 (0.57–1.35) 0.6 16 (7) 0.98 (0.51–1.87) 0.9
>30 10 (4) 0.46 (0.22–0.97) 0.04 42 (18) 0.78 (0.50–1.21) 0.3 14 (6) 0.81 (0.41–1.61) 0.6
BMI, body mass index; ICU, intensive care unit; OR, odds ratio; REF, reference.
aModels adjusted for age, functional status, prior pneumococcal vaccination, chest radiograph confirmation and Pneumonia Severity Index.
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lower and this would yield spuriously lower mortality rates
[26]. In our study, this is not likely as diabetes mellitus was the
only maldistributed co-morbidity, and obese individuals were on
more medications compared with the reference group. Last,
higher BMI may directly lead to better outcomes and lower
pneumonia-related mortality [12,14,15].
Why might obese patients with pneumonia have a survival
advantage? First, obese patients may have increased nutri-
tional reserves, which may help mitigate metabolic and
inflammatory stress [8]. Second, some authors have sug-
gested that ‘casting’ of the thoracic cavity (i.e. ‘strapping’ due
to relatively increased chest wall adiposity) can reduce
mechanical lung injury in the setting of pneumonia and other
conditions by reducing transpulmonary pressure-mediated
lung damage [29]. Third, although obesity is associated with
impaired inflammation in general [4], it is also true that
leptin production is increased in obesity and leptin enhances
CD4 lymphocyte response towards T helper type 1 cells [8].
Clearly, much work remains to be done to elucidate the
potential mechanism for protection related to obesity, espe-
cially in the setting of acute infections.
Several limitations of this study should be considered. First,
only 27% of the cohort had BMI measured and documented and
we have no information regarding the reasons for (or for not)
documenting weight; in general, it is part of routine care. In com-
paring the characteristics of individuals with missing and available
data (Appendix 1), few statistically significant and no clinically
important differences were noted. Second, we could not distin-
guish between lean and adipose tissue or central and peripheral
obesity, and we had no direct measure of nutritional reserves.
Third, it is possible that the obese patients in our cohort, admit-
ted to hospital with a clinical diagnosis of pneumonia, did not in
fact have pneumonia but instead had less serious respiratory
tract infections such as acute bronchitis or were misdiagnosed
with pneumonia but had shortness of breath or fever for other
reasons. Although chest radiographs are an imperfect reference
standard for pneumonia [23], our results were unaltered when
we restricted analyses to patients with abnormal chest radio-
graphs demonstrating pulmonary infiltrates.
In conclusion, our study suggests that obese individuals
with pneumonia are at significantly and substantially lower
risk of mortality than normal weight individuals. Our study
adds importantly to the reverse epidemiology literature and
we believe it justifies the need to undertake more fundamen-
tal and mechanistic work to better understand the reasons
for the obesity paradox in pneumonia.
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TABLE 5. Fatal and non-fatal endpoints in 680 patients hospitalized with pneumonia and abnormal chest radiographs accord-
ing to categories of body mass index
BMI
categories
(kg/m2)
Death,
n (%)
Adjusted *
OR
(95% CI) p-value
Transfer to
ICU, n (%)
Adjusted *
OR
(95% CI) p-value
30-day
readmission,
n (%)
Adjusted *
OR (95% CI) p-value
<18.5 12 (17) 1.27 (0.58–2.81) 0.6 12 (17) 0.56 (0.27–1.16) 0.1 5 (7) 0.87 (0.31–2.45) 0.8
18.5–25 30 (11) 1.00 REF 66 (24) 1.00 REF 20 (7) 1.00 REF
25.1–30 19 (11) 0.98 (0.52–1.88) 0.9 40 (24) 0.93 (0.58–1.50) 0.8 10 (6) 0.80 (0.36–1.76) 0.6
>30 6 (4) 0.31 (0.12–0.78) 0.01 32 (20) 0.74 (0.45–1.23) 0.3 12 (7) 1.09 (0.52–2.31) 0.8
BMI, body mass index; ICU, intensive care unit; OR, odds ratio; REF, reference.
*Models adjusted for age, functional status, prior pneumococcal vaccination, chest radiograph confirmation and Pneumonia Severity Index.
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Appendix 1
Comparison of the characteristics of patients with available vs. missing body mass index data.
Characteristic Available data N = 907 Missing data N = 2508 p-value
Age, mean ± SD, years 68 ± 17 69 ± 18 0.37
Female, n (%) 476 (52) 1327 (53) 0.82
Non-smoker, n (%) 652 (72) 1914 (76) 0.008
Impaired function, n (%) 101 (11) 262 (10) 0.56
Advanced directive, n (%) 89 (10) 296 (12) 0.11
Nursing home, n (%) 150 (17) 487 (19) 0.06
Co-morbidities, n (%)
Cardiovascular 456 (50) 1204 (48) 0.24
COPD 299 (33) 758 (30) 0.13
Diabetes mellitus 51 (6) 139 (6) 0.93
Known cancer 117 (13) 382 (15) 0.09
Chronic kidney disease 134 (15) 356 (14) 0.67
>5 medications, n (%) 155 (17) 395 (16) 0.35
Statins, n (%) 91 (10) 234 (9) 0.54
Pneumovax, n (%) 287 (32) 775 (31) 0.68
Flu vaccine, n (%) 242 (27) 663 (26) 0.89
SIRS >2, n (%) 716 (79) 2028 (81) 0.21
Hyperglycaemia >6.1, n (%) 580 (64) 1496 (60) 0.02
Respiratory rate >30, n (%) 206 (24) 584 (24) 0.85
Pneumonia severity index, n (%)
Class I/II/III 332 (37) 955 (38) 0.43
Class IV/V 575 (63) 1553 (62)
Abnormal chest radiograph, n (%) 680 (75) 1767 (70) 0.01
Appendix 2
Univariable and multivariable analysis of the need for intensive care unit transfer of 907 patients with pneumonia.
Unadjusted odds ratio (95% CI) p-value Adjusted * odds ratio (95% CI) p-value
BMI group
<18.5 0.65 (0.34–1.23) 0.18 0.55 (0.28–1.09) 0.09
18.5–25 1.00 REF 1.00 REF
25–30 0.87 (0.58–1.31) 0.50 0.88 (0.57–1.35) 0.55
> = 30 0.76 (0.50–1.15) 0.20 0.78 (0.50–1.21) 0.26
Age > 65 years 0.40 (0.29–0.56) <0.001 0.24 (0.16–0.36) <0.001
Pneumonia Severity Index Class IV/V 1.81 (1.26–2.60) 0.002 3.34 (2.17–5.12) <0.001
Impaired function 1.97 (1.24–3.12) 0.004 1.96 (1.20–3.20) 0.008
Abnormal chest radiograph 1.93 (1.26–2.97) 0.003 1.79 (1.14–2.81) 0.01
*c-statistic = 0.71, p <0.001; Hosmer-Lemeshow goodness-of-fit test, p 0.60.
Appendix 3
Univariable and multivariable analysis of the 30-day rates of readmission to hospital after surviving pneumonia and being dis-
charged to the community.
Unadjusted odds ratio (95% CI) p-value Adjusted * odds ratio (95% CI) p-value
BMI group
<18.5 1.53 (0.69–3.41) 0.29 1.48 (0.66–3.33) 0.34
18.5–25 1.00 REF 1.00 REF
25–30 0.96 (0.51–1.84) 0.91 0.98 (0.51–1.87) 0.95
> = 30 0.80 (0.41–1.57) 0.52 0.81 (0.41–1.61) 0.55
Age > 65 years 1.23 (0.71–2.13) 0.45 1.20 (0.65–2.22) 0.56
Pneumonia Severity Index Class IV/V 0.92 (0.55–1.54) 0.75 0.76 (0.43–1.35) 0.36
Impaired function 1.92 (0.99–3.72) 0.06 1.86 (0.94–3.66) 0.07
Pneumovax 1.38 (0.82–2.33) 0.54 1.34 (0.78–2.32) 0.27
Abnormal chest radiograph 0.86 (0.49–1.52) 0.61 0.84 (0.47–1.49) 0.54
*c-statistic = 0.68, p <0.001; Hosmer-Lemeshow goodness-of-fit test, p 0.68.
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